Skip to main content
This R&D Website is for US Healthcare Professionals Only

Approved Drugs

Approved Drugs

Our passion, partnerships and collaborations enable us to develop first-in-class medicines that aim to potentially transform the way cancer is treated. Below is a list of drugs and their approved indications.

Venetoclax

On April 12, 2016, under accelerated approval conditions, the US Food and Drug Administration approved venetoclax tablets, the first BCL-2 inhibitor in relapsed/refractory chronic lymphocytic leukemia patients with 17p deletion who have received at least one prior treatment.

This drug is co-developed by AbbVie, Inc. and Genentech USA, Inc.

Learn more about venetoclax on this website and access its safety profile along with full prescribing information.


Elotuzumab

The US Food and Drug Administration has approved elotouzumab in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received one to three prior therapies.

This drug is co-developed by AbbVie, Inc. and Bristol-Myers Squib.

Learn more about elotuzumab on this website and access its safety profile along with full prescribing information.


Ibrutinib

The US Food and Drug Administration has approved the kinase inhibitor ibrutinib for the treatment of patients with mantle cell lymphoma who have received at least one prior treatment, chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL), CLL and SLL with 17p deletion, and Waldenström's macroglobulinemia (WM).

This drug is developed by Pharmacyclics LLC, a wholly owned subsidiary of AbbVie, focused on developing and commercializing innovative small molecule drugs for the treatment of cancer and immune-mediated diseases.

Learn more about ibrutinib on this website and access its safety profile along with full prescribing information.